Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | RELA | Q04206 | 3/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHAT | P28329 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4304905 | 0.97 | NFE2L2 (0.56) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL4304901 | 0.97 | NFE2L2 (0.56) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL30129708 | 0.97 | NFE2L2 (0.56) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL28618279 | 0.89 | KMT2A (0.49) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL28604671 | 0.89 | CYP19A1 (0.75) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL27725975 | 0.88 | CA1 (0.50) | NFE2L2MAOBCYP19A1MAOAMEN1 | |
| SCHEMBL9971852 | 0.86 | MAOB (0.52) | NFE2L2MAOBCYP19A1MAOAMEN1 | |
| SCHEMBL9971876 | 0.86 | NFE2L2 (0.47) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL1628768 | 0.85 | NFE2L2 (0.42) | NFE2L2MAOBCYP19A1MAOARELA | |
| SCHEMBL13897126 | 0.85 | RELA (0.52) | NFE2L2MAOBCYP19A1MAOARELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035576-A1 | Nanoparticles for two-photon activated photodynamic therapy and imaging | HEALTH RESEARCH, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20080233051-A1 | Nanoparticles for two-photon activated photodynamic therapy and imaging | HEALTH RESEARCH, INC. | 2008-09-25 | — | — | US | disclosed |
| WO-2008030624-A2 | NANOPARTICLES FOR TWO-PHOTON ACTIVATED PHOTODYNAMIC THERAPY AND IMAGING | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080233051-A1 | Nanoparticles for two-photon activated photodynamic therapy and imaging | ORMDL3, PPOX, ORC3 | NFE2L2 83/4885MAOB 3848/4885CYP19A1 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.